Kenneth E.J. Dickinson

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

37

H-Index

1

About

Kenneth E.J. Dickinson is a distinguished pharmaceutical scientist whose work has significantly advanced the field of drug metabolism and pharmacokinetics. His research centers on developing high-throughput analytical methodologies to assess the metabolic stability of drug candidates, a critical step in early-stage drug discovery. Dickinson’s most notable contribution is the creation of the MetFast assay, an automated liquid chromatography–mass spectrometry process that enables rapid, in vitro evaluation of microsomal cytochrome P450-mediated first-pass metabolism. This innovation, detailed in his highly cited 2007 paper (37 citations), has become a foundational tool for pharmaceutical profiling, allowing researchers to efficiently screen compounds for metabolic stability and prioritize promising leads. By streamlining the assessment of drug candidates, Dickinson’s work has helped reduce attrition rates in development pipelines and accelerate the identification of viable therapeutics. His contributions underscore the importance of integrating automation and mass spectrometry into preclinical drug evaluation, making him a key figure in modern pharmaceutical research.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates
37 citations · 2007
📈 Most Prolific Year: 2007 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago